Business Description
NeoGenomics Inc
NAICS : 541714
SIC : 8734
ISIN : US64049M2098
Total Employee Number:
2,500Description
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.36 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.49 | |||||
Debt-to-EBITDA | -12.4 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.24 | |||||
Beneish M-Score | -2.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.4 | |||||
3-Year EBITDA Growth Rate | 23.1 | |||||
3-Year FCF Growth Rate | 39.8 | |||||
3-Year Book Growth Rate | -6.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 64.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.88 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 91.09 | |||||
9-Day RSI | 84.13 | |||||
14-Day RSI | 79.54 | |||||
3-1 Month Momentum % | 19.46 | |||||
6-1 Month Momentum % | -24.51 | |||||
12-1 Month Momentum % | 29.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.42 | |||||
Quick Ratio | 4.06 | |||||
Cash Ratio | 1.73 | |||||
Days Inventory | 25.96 | |||||
Days Sales Outstanding | 76.95 | |||||
Days Payable | 19.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | 10.65 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 43.15 | |||||
Operating Margin % | -10.53 | |||||
Net Margin % | -13.3 | |||||
EBITDA Margin % | -4.42 | |||||
FCF Margin % | -0.68 | |||||
OCF Margin % | 3.01 | |||||
ROE % | -11.68 | |||||
ROA % | -7.01 | |||||
ROIC % | -6.4 | |||||
3-Year ROIIC % | -51.57 | |||||
ROC (Joel Greenblatt) % | -33.06 | |||||
ROCE % | -7.74 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 78.72 | |||||
PS Ratio | 2.44 | |||||
PB Ratio | 2.22 | |||||
Price-to-Tangible-Book | 70.85 | |||||
Price-to-Operating-Cash-Flow | 80.97 | |||||
EV-to-EBIT | -21.19 | |||||
EV-to-Forward-EBIT | 196.15 | |||||
EV-to-EBITDA | -63.97 | |||||
EV-to-Forward-EBITDA | 318.29 | |||||
EV-to-Revenue | 2.83 | |||||
EV-to-Forward-Revenue | 2.49 | |||||
EV-to-FCF | -414.21 | |||||
Price-to-GF-Value | 0.85 | |||||
Price-to-Projected-FCF | 15.24 | |||||
Price-to-Median-PS-Value | 0.7 | |||||
Earnings Yield (Greenblatt) % | -4.72 | |||||
FCF Yield % | -0.28 | |||||
Forward Rate of Return (Yacktman) % | -8.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NEO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NeoGenomics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 745.969 | ||
| EPS (TTM) ($) | -0.77 | ||
| Beta | 2.343 | ||
| 3-Year Sharpe Ratio | 0.07 | ||
| 3-Year Sortino Ratio | 0.12 | ||
| Volatility % | 106.48 | ||
| 14-Day RSI | 79.54 | ||
| 14-Day ATR ($) | 0.679715 | ||
| 20-Day SMA ($) | 11.314 | ||
| 12-1 Month Momentum % | 29.47 | ||
| 52-Week Range ($) | 4.72 - 14.23 | ||
| Shares Outstanding (Mil) | 130.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NeoGenomics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeoGenomics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-28 08:30 | In 123 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 122 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:30 | In 32 days | ||
| Second quarter earnings results for 2026 | 2026-07-29 | In 31 days | ||
| The Jefferies Global Healthcare Conference | 2026-06-04 10:30 | 10.14 (+0.60%) | ||
| General meeting for 2026 | 2026-05-21 10:00 | 8.90 (+5.95%) | ||
| First quarter earnings conference call for 2026 | 2026-04-28 16:30 | 8.61 (+3.86%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 8.61 (+3.86%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 16:20 | 8.93 (+0.56%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 13:10 | 9.50 (-2.26%) |
Show
Entries
NeoGenomics Inc Frequently Asked Questions
What is NeoGenomics Inc(NEO)'s stock price today?
The current price of NEO is $14.17. The 52 week high of NEO is $14.23 and 52 week low is $4.72.
When is next earnings date of NeoGenomics Inc(NEO)?
The next earnings date of NeoGenomics Inc(NEO) is 2026-07-29 Est..
Does NeoGenomics Inc(NEO) pay dividends? If so, how much?
NeoGenomics Inc(NEO) does not pay dividend.
Guru Commentaries on NAS:NEO
No articles.
Press Release
Articles on NeoGenomics Inc
No articles.
Headlines
See More- 1
Jun 17, 2026
NeoGenomics prices $275M convertible notes due 2032, plans repurchases of 2028 notes and shares
Seeking Alpha • 5:28am
Jun 15, 2026
NeoGenomics launches $275M convertible notes offering due 2032
Seeking Alpha • 4:56pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers